Nootropics Index - Save on smarter supplements
Hormones & endocrine-related compounds

S-23

S-23

S-23 is an experimental selective androgen receptor modulator (SARM), with mainly animal evidence. Our moderate 3/5 risk rating is a provisional editorial estimate with very low confidence, based on animal hormone findings and indirect human SARM-class data. It is not a measured probability of harm or a safety threshold.

Hormonal Axis RelatedSyntheticMostly Animal EvidenceInsufficient EvidenceModerate Risk ProfileCardiovascular CautionLiver Caution
Updated October 2026/6 min read/8 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

What it is

4

S-23 is a synthetic selective androgen receptor modulator, a compound designed to bind the receptor used by androgens such as testosterone. Its experimental research includes rat models of hormonal male contraception.

Evidence snapshot4
Animal findings cannot establish muscle, endurance or cognitive benefits in people. No controlled human S-23 efficacy or typical-dose safety study was identified in the sources reviewed.
02

Names, aliases and forms

Common NameS-23
Research CodeS23
Regulatory NameSelective androgen receptor modulator
AcronymSARM
03

Mechanisms of action

Androgen-receptor agonism

4

S-23 binds and activates the androgen receptor in preclinical experiments. Receptor selectivity does not by itself demonstrate safety in humans.

Hormone-axis suppression

4

S-23 alone suppressed luteinizing hormone (LH), a reproductive hormone signal, in male rats. The separate contraception experiment combined S-23 with the estrogen estradiol benzoate and produced reversible infertility in that model. These results do not establish human infertility rates or recovery.

04

Potential effects and evidence map

S-23 animal studies show androgen-receptor activity and reproductive effects. Human cognition and performance benefits remain unestablished. A human trial of the different SARM LGD-4033 supports indirect hormone and lipid concerns, not S-23-specific clinical outcomes. The provisional risk estimate has very low confidence.

Effect domainMagnitudeGrade
Physical energy / endurance4
UnknownConfidence: Low

Animal S-23 data show androgenic/anabolic tissue effects, but that is not human strength, endurance, or performance evidence.

Note Rat lean-mass findings do not establish a muscle, strength or endurance benefit in people.

1/5
D
05

Timing & effect horizon

Effect horizonUnknown
Unknown
Effect timing and cycles5

The available animal and anti-doping studies do not establish a human effect onset, The time for blood levels to fall by half during the final elimination phase.Source, duration or safe cycle. Equine metabolite detection is a laboratory measurement, not a human effect window.

06

Safety, side effects and risk profile

Provisional moderate risk: very low confidence4
Moderate 3/5 is an editorial estimate from animal hormone and fertility signals plus cautious extrapolation from human SARM-class hormone and lipid changes. Minimal and low would understate these biologically meaningful signals. High or critical would overstate the available S-23-specific human evidence. This is not a measured harm probability, validated healthy-adult baseline or safety threshold; dose, duration, likelihood and reversibility in people remain unquantified.
Pregnancy and breastfeeding2
Pregnancy and breastfeeding safety for S-23 is unestablished. FDA includes miscarriage and reproductive harm among SARM-product concerns; these cautions apply separately from the provisional adult risk estimate.
Hormonal caution4
Confidence: Low

Provisional hormone-risk estimate with very low confidence: S-23 suppressed reproductive hormones in rats; human likelihood, severity and recovery are unquantified.

Note Confidence is very low because the evidence is indirect. This editorial score cannot establish a safe human dose or the probability of harm.

3/5
D
What human class evidence adds8

In a placebo-controlled study of 76 healthy men, the different SARM LGD-4033 lowered testosterone and HDL cholesterol over 21 days; measured hormone and lipid changes recovered after discontinuation. No drug-related serious adverse events were reported. This supports a cautious class analogy, not proof of the same effects or recovery with S-23. HDL changes alone do not establish cardiovascular event risk.

Liver and cardiovascular warnings2

FDA warns that SARM products have been associated with liver injury and potentially serious cardiovascular events. These class-level reports do not establish the frequency, dose threshold or reversibility of harm from S-23 itself.

Product identity and dose risk6

A 2017 analysis of 44 internet products marketed as SARMs found frequent discrepancies in identity and labeled amount. It was a historical class-market sample, not testing of the S-23 offers displayed here.

07

Interactions and cautions

Interaction evidence is missing7

The reviewed S-23 evidence does not establish compatibility with medicines, other hormones, supplements or alcohol. A lack of documented interactions is not proof that combinations are safe.

09

Practical buying and quality notes

  • For capsule listings, compare package count and labeled amount per capsule before comparing price. A price per capsule is not a price per verified milligram and says nothing about a safe dose. The displayed offer links are navigation, not approval for human use.6
  • Check whether a certificate of analysis identifies the same batch and measures chemical identity and amount. Even a matching assay cannot establish human safety or efficacy. Historical SARM mislabeling findings do not prove that a particular current listing is mislabeled.6
10

FAQ

What human dose has been established?

4

A validated human S-23 dose is not established. Amounts printed on retail capsules are product-label information; animal experimental doses cannot supply a self-use schedule.

Is there an evidence-based S-23 cycle length?

5

No human cycle length has been validated in the reviewed evidence. Animal study schedules and anti-doping detection periods cannot define how long human effects last or establish a safe cycle.

11

References

  1. World Anti-Doping Agency. The 2026 Prohibited List: International Standard.
  2. U.S. Food and Drug Administration. Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more.
  3. Operation Supplement Safety (OPSS). SARMs Handout.
  4. Jones A, Chen J, Hwang DJ, Miller DD, et al. Preclinical characterization of S-23: a selective androgen receptor modulator for hormonal male contraception. Endocrinology. 2009;150(1):385-395.
  5. Cutler C, Viljanto M, Hincks P, Habershon-Butcher J, et al. Detection of the selective androgen receptor modulator S-23 and its metabolites in equine urine and plasma following oral administration. Drug Test Anal. 2025;17(5):601-611.
  6. Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, et al. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA. 2017;318(20):2004-2010.
  7. Christiansen AR, Lipshultz LI, Hotaling JM, Pastuszak AW. Selective androgen receptor modulators: the future of androgen therapy? Transl Androl Urol. 2020;9(Suppl 2):S135-S148.
  8. Basaria S, Collins L, Dillon EL, et al. The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men. J Gerontol A Biol Sci Med Sci. 2013;68(1):87-95.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.